Beetroot Juice, Exercise and a Heart Drug Face Off in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy is the most common genetic cardiovascular disease, with a broad spectrum of severity ranging from asymptomatic to severely limiting. Treatment options remain limited, focused mainly on symptom relief rather than modifying the underlying disease process. Finding interventions that genuinely improve exercise capacity and quality of life in HCM patients is a pressing clinical priority.

This five-center, open-label, three-arm Phase 2 pilot trial enrolled 168 patients with HCM to evaluate two distinct intervention strategies. One arm was a lifestyle intervention combining structured physical activity with inorganic nitrate supplementation in the form of concentrated nitrate-rich beetroot juice. Another arm was a pharmacological intervention using sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor that has demonstrated mortality and hospitalization benefits in heart failure populations. The exact composition of the third arm is not specified in the available abstract.

The biological rationale for each arm is well grounded. Dietary nitrate improves vasodilation, cardiac output reserve, and reduces arterial wave reflections linked to left ventricular diastolic dysfunction and remodeling. Exercise training consistently raises exercise tolerance in HCM, even if it has limited effects on cardiac morphology or function. Sacubitril/valsartan has been shown to improve cardiac function and exercise tolerance in heart failure, mechanisms potentially relevant to HCM pathophysiology.

Primary outcomes focused on functional capacity, clinical phenotypic markers, and quality of life. Results from this completed trial have not yet been incorporated into major guidelines, and published outcome data were not available in the abstract reviewed here.

If either intervention proves effective, the implications are substantial. A safe, low-cost lifestyle protocol involving beetroot juice and exercise could be deployed broadly, while sacubitril/valsartan would represent a repurposed drug with a mechanistic rationale for HCM. Clinicians managing HCM patients should watch for full publication of these results.